Replies to post #7259 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Thanks. HALO PR department has some updating to do on their parter pipeline chart, both for
Nivolumab + Relatlimab (phase 1 to phase 3) and for Efgartigimod (now filed)
https://halozyme.com/enhanze/#pipeline_group_1